JSB Market Research: Schizophrenia - Pipeline Review, H1 2014
This report "Schizophrenia - Pipeline Review, H1 2014'' provides comprehensive information on the therapeutic development for Schizophrenia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.
This report "Schizophrenia - Pipeline Review, H1 2014'' provides comprehensive information on the therapeutic development for Schizophrenia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Number of Products under Development for <strong>Schizophrenia</strong>, <strong>H1</strong> <strong>2014</strong> 25<br />
Number of Products under Development for <strong>Schizophrenia</strong> - Comparative Analysis, <strong>H1</strong> <strong>2014</strong> 26<br />
Number of Products under Development by Companies, <strong>H1</strong> <strong>2014</strong> 28<br />
Number of Products under Development by Companies, <strong>H1</strong> <strong>2014</strong> (Contd..1) 29<br />
Number of Products under Development by Companies, <strong>H1</strong> <strong>2014</strong> (Contd..2) 30<br />
Number of Products under Development by Companies, <strong>H1</strong> <strong>2014</strong> (Contd..3) 31<br />
Number of Products under Development by Companies, <strong>H1</strong> <strong>2014</strong> (Contd..4) 32<br />
Number of Products under Development by Companies, <strong>H1</strong> <strong>2014</strong> (Contd..5) 33<br />
Number of Products under Investigation by Universities/Institutes, <strong>H1</strong> <strong>2014</strong> 35<br />
Comparative Analysis by Late Stage Development, <strong>H1</strong> <strong>2014</strong> 36<br />
Comparative Analysis by Clinical Stage Development, <strong>H1</strong> <strong>2014</strong> 37<br />
Comparative Analysis by Early Stage Development, <strong>H1</strong> <strong>2014</strong> 38<br />
Comparative Analysis by Unknown Stage Development, <strong>H1</strong> <strong>2014</strong> 39<br />
Products under Development by Companies, <strong>H1</strong> <strong>2014</strong> 40<br />
Products under Development by Companies, <strong>H1</strong> <strong>2014</strong> (Contd..1) 41<br />
Products under Development by Companies, <strong>H1</strong> <strong>2014</strong> (Contd..2) 42<br />
Products under Development by Companies, <strong>H1</strong> <strong>2014</strong> (Contd..3) 43<br />
Products under Development by Companies, <strong>H1</strong> <strong>2014</strong> (Contd..4) 44<br />
Products under Development by Companies, <strong>H1</strong> <strong>2014</strong> (Contd..5) 45<br />
Products under Development by Companies, <strong>H1</strong> <strong>2014</strong> (Contd..6) 46<br />
Products under Development by Companies, <strong>H1</strong> <strong>2014</strong> (Contd..7) 47<br />
Products under Development by Companies, <strong>H1</strong> <strong>2014</strong> (Contd..8) 48<br />
Products under Investigation by Universities/Institutes, <strong>H1</strong> <strong>2014</strong> 49<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by Bristol-Myers Squibb Company, <strong>H1</strong> <strong>2014</strong> 50<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by Johnson & Johnson, <strong>H1</strong> <strong>2014</strong> 51<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by Boehringer Ingelheim GmbH, <strong>H1</strong> <strong>2014</strong> 52<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by F. Hoffmann-La Roche Ltd., <strong>H1</strong> <strong>2014</strong> 53<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by Eli Lilly and Company, <strong>H1</strong> <strong>2014</strong> 54<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by Athersys, Inc., <strong>H1</strong> <strong>2014</strong> 55<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by Alkermes Plc, <strong>H1</strong> <strong>2014</strong> 56<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by Merck & Co., Inc., <strong>H1</strong> <strong>2014</strong> 57<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by Dainippon Sumitomo Pharma Co., Ltd., <strong>H1</strong> <strong>2014</strong> 58<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by Taisho Pharmaceutical Co., Ltd., <strong>H1</strong> <strong>2014</strong> 59<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by NeuroDerm Ltd., <strong>H1</strong> <strong>2014</strong> 60<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by Takeda Pharmaceutical Company Limited, <strong>H1</strong> <strong>2014</strong> 61<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by Zogenix, Inc., <strong>H1</strong> <strong>2014</strong> 62<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by Neurocrine Biosciences, Inc., <strong>H1</strong> <strong>2014</strong> 63<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by Novartis AG, <strong>H1</strong> <strong>2014</strong> 64<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by EnVivo Pharmaceuticals, <strong>H1</strong> <strong>2014</strong> 65<br />
Email ID- contact@jsbmarketresearch.com<br />
Tel No- 91 2241236650<br />
Published by- http:/www.jsbmarketresearch.com/
Change language